PE20090162A1 - Tetrahidro-pirazolo-piridina ligada a carbono como moduladores de catepsina s - Google Patents

Tetrahidro-pirazolo-piridina ligada a carbono como moduladores de catepsina s

Info

Publication number
PE20090162A1
PE20090162A1 PE2008000334A PE2008000334A PE20090162A1 PE 20090162 A1 PE20090162 A1 PE 20090162A1 PE 2008000334 A PE2008000334 A PE 2008000334A PE 2008000334 A PE2008000334 A PE 2008000334A PE 20090162 A1 PE20090162 A1 PE 20090162A1
Authority
PE
Peru
Prior art keywords
phenyl
alkyl
tetrahydro
pyridine
pyrazolo
Prior art date
Application number
PE2008000334A
Other languages
English (en)
Inventor
Michael K Ameriks
Frank U Axe
Hui Cai
James P Edwards
Elizabeth Ann Gleason
Cheryl A Grice
Steven P Meduna
Kevin L Tays
Alvah T Wickboldt
John J M Wiener
Original Assignee
Sunesis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sunesis Pharmaceuticals Inc filed Critical Sunesis Pharmaceuticals Inc
Publication of PE20090162A1 publication Critical patent/PE20090162A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

REFERIDA A UN DERIVADO DE PIRIDINA DE FORMULA (I), DONDE R1 Y R2 TOMADOS JUNTOS CON EL NITROGENO AL CUAL ESTAN ENLAZADOS FORMAN UN GRUPO HETEROCICLOALQUILO MONOCICLICO SATURADO, DONDE CADA GRUPO CONTIENE UN MIEMBRO DEL ANILLO DE HETEROATOMO ADICIONAL QUE ES O, S, NRa, Y CADA GRUPO ESTA OPCIONALMENTE SUSTITUIDO CON Rb; Rb ES ALQUILO C1-C4, OH, CF3, ENTRE OTROS; Ra ES H, ALQUILO C1-C4, FENILO, ENTRE OTROS; R3 ES H, OH, ALQUILO C1-C4, ENTRE OTROS; R4 ES H, ALQUILO C1-C4, CO-FENIL, ENTRE OTROS; R5 ES HALO O CF3; R6 ES H O F; D ES CH=CH-R8, (CH2)2-3-R8, (CH2)3-5-R9, ENTRE OTROS; R8 ES FENILO O UN GRUPO HETEROARILO MONOCICLICO SUSTITUIDO OPCIONALMENTE CON Rk; Rk ES ALQUILO C1-C4, HALO, CN, COOH, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: 3-[4-CLORO-3-(1H-INDOL-5-ILETINIL)-FENIL]-5-METANOSULFONIL-1-(3-MOROFOLIN-4-IL-PROPIL)-4,5,6,7-TETRAHIDRO-1H-PIRAZOLO[4,3-c]PIRIDINA, 3-{4-CLORO-3-[2-(1H-INDOL-5-IL)-ETIL]-FENIL}-5-METANOSULFONIL-1-(3-MORFOLIN-4-IL-PROPIL)-4,5,6,7-TETRAHIDRO-1H-PIRAZOLO[4,3-c]PIRIDINA, (4-{2-CLORO-5-[5-METANOSULFONIL-1-(3-MORFOLIN-4-IL-PROPIL)-4,5,6,7-TETRAHIDRO-1H-PIRAZOLO[4,3-c]PIRIDIN-3-IL]-FENILETINIL}-FENIL)-ACETONITRILO, ENTRE OTROS. TAMBIEN ESTA REFERIDA A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON MODULADORES DE CATEPSINA S Y SON UTILES EN EL TRATAMIENTO DE TRANSTORNOS INTESTINALES, LUPUS, ASMA, REACCIONES ALERGICAS, TRANSTORNOS DEL SISTEMA INMUNOLOGICO, ENTRE OTROS
PE2008000334A 2007-02-15 2008-02-15 Tetrahidro-pirazolo-piridina ligada a carbono como moduladores de catepsina s PE20090162A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US88997707P 2007-02-15 2007-02-15
US12/031,010 US20080200454A1 (en) 2007-02-15 2008-02-14 Carbon-linked tetrahydro-pyrazolo-pyridine modulators of cathepsin s

Publications (1)

Publication Number Publication Date
PE20090162A1 true PE20090162A1 (es) 2009-03-12

Family

ID=39512608

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008000334A PE20090162A1 (es) 2007-02-15 2008-02-15 Tetrahidro-pirazolo-piridina ligada a carbono como moduladores de catepsina s

Country Status (8)

Country Link
US (1) US20080200454A1 (es)
AR (1) AR065377A1 (es)
CL (1) CL2008000495A1 (es)
PA (1) PA8769601A1 (es)
PE (1) PE20090162A1 (es)
TW (1) TW200843743A (es)
UY (1) UY30921A1 (es)
WO (1) WO2008100618A2 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009102937A1 (en) * 2008-02-14 2009-08-20 Sunesis Pharmaceuticals, Inc. Processes for the preparation of carbon-linked tetrahydro-pyrazolo-pyridine modulators of cathepsin s
WO2011069149A2 (en) * 2009-12-04 2011-06-09 Dcb-Usa Llc Cathepsin s inhibitors
WO2011094890A1 (en) * 2010-02-02 2011-08-11 Argusina Inc. Phenylalanine derivatives and their use as non-peptide glp-1 receptor modulators
EP2585066B1 (en) * 2010-06-24 2018-09-26 Alkermes Pharma Ireland Limited Prodrugs of nh-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives
BR112013012836A2 (pt) 2010-11-24 2019-09-24 Allergan Inc moduladores dos receptores s1p"
CN107709314A (zh) 2015-06-11 2018-02-16 巴斯利尔药物国际股份公司 外排泵抑制剂及其治疗性用途
CN106916094B (zh) * 2017-01-11 2019-06-04 青岛昌泰和生物科技有限公司 一种吲哚二酮化合物的制备方法
WO2019074241A1 (ko) * 2017-10-11 2019-04-18 정원혁 페닐아세틸렌 유도체를 포함하는 pd-1과 pd-l1의 상호작용 억제제
US20220193048A1 (en) 2019-04-05 2022-06-23 Universite De Bretagne Occidentale Protease-activated receptor-2 inhibitors for the treatment of sensory neuropathy induced by a marine neurotoxic poisoning

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7332494B2 (en) * 2000-08-14 2008-02-19 Janssen Pharmaceutica, N.V. Method for treating allergies using substituted pyrazoles
DE60126286T2 (de) * 2000-08-14 2007-11-15 Ortho-Mcneil Pharmaceutical, Inc. Substituierte pyrazole
US20070117785A1 (en) * 2000-08-14 2007-05-24 Butler Christopher R Substituted pyrazoles and methods of treatment with substituted pyrazoles
AU2001284823B2 (en) * 2000-08-14 2006-11-30 Ortho-Mcneil Pharmaceutical, Inc. Substituted pyrazoles
EP1309593B1 (en) * 2000-08-14 2006-03-15 Ortho-McNeil Pharmaceutical, Inc. Substituted pyrazoles
US20050101587A9 (en) * 2000-08-14 2005-05-12 Butler Christopher R. Method for treating allergies using substituted pyrazoles
US20070105841A1 (en) * 2000-08-14 2007-05-10 Breitenbucher J G Method for treating allergies using substituted pyrazoles
NZ524681A (en) * 2000-09-06 2005-09-30 Ortho Mcneil Pharm Inc A method for treating allergies using substituted pyrazoles
AU2001288714A1 (en) * 2000-09-06 2002-03-22 Ortho-Mcneil Pharmaceutical, Inc. A method for treating allergies
US20030144234A1 (en) * 2001-08-30 2003-07-31 Buxton Francis Paul Methods for the treatment of chronic pain and compositions therefor
US20030073672A1 (en) * 2001-09-05 2003-04-17 Breitenbucher J. Guy Method for treating allergies using substituted pyrazoles
SE0201977D0 (sv) * 2002-06-24 2002-06-24 Astrazeneca Ab Novel compounds
SE0201980D0 (sv) * 2002-06-24 2002-06-24 Astrazeneca Ab Novel compounds
SE0201976D0 (sv) * 2002-06-24 2002-06-24 Astrazeneca Ab Novel compounds
GB0304640D0 (en) * 2003-02-28 2003-04-02 Novartis Ag Organic compounds
US7173051B2 (en) * 2003-06-13 2007-02-06 Irm, Llc Inhibitors of cathepsin S
US7326715B2 (en) * 2005-09-23 2008-02-05 N.V. Organon 4-Phenyl-6-substituted-pyrimidine-2-carbonitrile derivatives
US7687515B2 (en) * 2006-01-17 2010-03-30 N.V. Organon 6-phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile derivatives

Also Published As

Publication number Publication date
PA8769601A1 (es) 2009-03-31
WO2008100618A3 (en) 2008-10-02
WO2008100618A2 (en) 2008-08-21
TW200843743A (en) 2008-11-16
AR065377A1 (es) 2009-06-03
UY30921A1 (es) 2008-09-02
US20080200454A1 (en) 2008-08-21
CL2008000495A1 (es) 2008-11-03

Similar Documents

Publication Publication Date Title
PE20090162A1 (es) Tetrahidro-pirazolo-piridina ligada a carbono como moduladores de catepsina s
AR082985A1 (es) INHIBIDORES DE PI3K-d Y METODOS DE SU USO Y PREPARACION
WO2007027775A3 (en) Methods for use in modulating mir-122a
EA201100877A1 (ru) Спирогетероциклические n-оксиамиды в качестве пестицидов
BR112014009302B1 (pt) processo para preparar derivados de quinolina
ECSP077424A (es) Derivados de quinuclidina y su uso como antagonistas del receptor muscarínico m3
AR065354A1 (es) Derivados de 2-aminopirimidina, un metodo para su preparacion, una composicion farmaceutica que lo comprende y su uso en el tratamiento de enfermedades mediadas por el receptor de histamina h4.
EA201391313A1 (ru) C4-монометилтритерпеноидные производные и способы их применения
AR085149A1 (es) Moduladores del receptor de glucagon
NZ604306A (en) Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued -3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of protein kinases
EA201170769A1 (ru) Органические соединения
MY154962A (en) Crystalline forms and processes for the preparation of phenyl-pyrazoles useful as modulators of the 5-ht2a seratonin receptor
AR064027A1 (es) Proceso quimico para preparar rosuvastatina y su sal de sodio y/o calcio
EA201400771A1 (ru) Новые производные азетидина, фармацевтические композиции и их применение
AU2008255733A8 (en) Novel 1,2,3,4-tetrahydroquinoxaline derivative which has, as substituent, phenyl group having sulfonic acid ester structure or sulfonic acid amide structure introduced therein and has glucocorticoid receptor-binding activity
WO2011132051A3 (en) Tricycle compounds as phosphodiesterase-10 inhibitors
WO2011098408A3 (de) Hydrazin-substituierte anthranilsäurederivate
CR9885A (es) Metodos para preparar derivados de acido glutamico
WO2012099952A3 (en) Benzofuro[3,2-c] pyridines and related analogs as serotonin sub-type 6 (5-ht6) modulators for the treatment of obesity, metabolic syndrome, cognition and schizophrenia
UY30740A1 (es) Nuevo procedimiento para la preparacion de 4,4??-( 1-metil-1,2-etandilil)-bis-(2,6-piperazindiona)
Uenoyama et al. Synthesis of lactams by radical substitution reaction of α, β-unsaturated acyl radicals at amine nitrogen
Pasco et al. Stereoselective synthesis of fluorinated 1, 3-cis-diaminocyclopentanes
Grange et al. Metal-free metathesis reaction of C-chiral allylic sulfilimines with aryl isocyanates: Construction of chiral nonracemic allylic isocyanates
Winkler et al. Synthesis of novel heterocyclic structures via reaction of isocyanides with s-trans-enones
Solovyev et al. One-pot synthesis of substituted 2-aminobenzo [b] thiophenes

Legal Events

Date Code Title Description
FD Application declared void or lapsed